维亚生物(01873)绩前抢跑，截至发稿，涨8.76%，报2.11港元，成交额2609.22万港元。

消息面上，维亚生物拟于3月27日举行董事会会议审批年度业绩。公司此前发布盈喜，与上年度股东应占净亏损1.16亿人民币相比，预计2024年度股东应占净利润介乎1.5亿至1.8亿人民币。扭亏为盈主要因合同研究组织业务下半年恢复增长、营运效率提升令经营利润率上升以及年内收到里程碑付款确认投资收益。

招商证券发研报称，公司作为全球蛋白解析领域龙头，凭借在SBDD领域的独特优势，打造AI+药物研发创新模式，为客户提供FIC药物研发服务；同时，公司通过收购朗华制药、自建CMC，打造一站式原创新药物研发平台和生产服务平台。该行观察到，2024年全球投融资环境逐步回暖，公司CRO订单稳步恢复，朗华服务项目研发进度持续向后期推进，为公司业绩提供有力支撑。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.